Value
7.9/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 6.2 |
| Analyst target | 9.0 |
- ▸Attractively valued
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
4D Molecular Therapeutics is a pre-revenue biotech burning cash with quality scored 2.8/10 and moderate insider selling; the case rests on 139% analyst upside from a binary clinical outcome.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
| Pillar | Expectation | Trend |
|---|---|---|
The company is burning cash at -98% of revenue with a quality score of 2.8/10. Quality breakdown | Cash burn narrows and quality score recovers above 4.0. | →Stable |
| CounterCurrent ratio scores 6.8, indicating enough liquidity to fund trials for the next 12 months. | ||
The analyst target of $24.44 implies 138.9% upside from $10.23, versus 15% downside to the stop. Targets | Price moves toward the $24.44 target as clinical milestones are reached. | ↑Improving |
| CounterIn a binary biotech, one failed trial can erase the value and make the analyst target worthless. | ||
Recent quarters show persistent small misses: 3 of the last 4 missed, with EPS near -$1.0 per quarter. Earnings | Quarterly losses stay at or below $1.10 per share. | ↓Deteriorating |
| CounterThe misses are small (about 1-3%), and the March quarter beat by 181%, so losses are broadly in line with plan. | ||
Insiders are selling $1,616,428, which is 0.280% of market cap and flagged as notable selling. Insider breakdown | Insider selling fades below 0.1% of market cap. | ↓Deteriorating |
| CounterScheduled selling by biotech executives often reflects diversification, not a negative view. | ||
Short interest is 22% with implied volatility of 214%, and momentum is weak at 2.1/10 despite a rising 200-day average. Risk breakdown | Short interest falls below 15% as clinical data improves. | ↓Deteriorating |
| CounterThe 200-day average is still rising 5.6% over 30 days, so this may be a pullback in an uptrend. | ||
CounterCurrent ratio scores 6.8, indicating enough liquidity to fund trials for the next 12 months.
CounterIn a binary biotech, one failed trial can erase the value and make the analyst target worthless.
CounterThe misses are small (about 1-3%), and the March quarter beat by 181%, so losses are broadly in line with plan.
CounterScheduled selling by biotech executives often reflects diversification, not a negative view.
CounterThe 200-day average is still rising 5.6% over 30 days, so this may be a pullback in an uptrend.
| Component | Sub-score |
|---|---|
| P/S | 6.2 |
| Analyst target | 9.0 |
| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Current ratio | 6.8 |
| FCF quality | 0.0 |
| Moat | 5.8 |
| Piotroski F | 4.4 |
| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 1.0 |
| OBV | 1.0 |
| MA position | 2.2 |
| Volume | 1.7 |
| Component | Sub-score |
|---|---|
| LLM sentiment | 4.0 |
| Analyst rating | 8.3 |
| Price target | 10.0 |
| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.0 |
| Component | Sub-score |
|---|---|
| value rank | 6.1 |
| quality rank | 1.0 |
| growth rank | 10.0 |
| Component | Sub-score |
|---|---|
| bollinger | 9.7 |
| support resistance | 9.6 |
| 52w position | 2.1 |
| gap | 7.0 |
| Component | Sub-score |
|---|---|
| short interest | 1.3 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 0.3 |
| debt equity | 9.5 |
| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 1.4 |
| news activity | 5.0 |
Quality below minimum threshold.
L1:HARD_BLOCK:QUALITY_FLOORSetup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.6B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 2.1<4.5 outcome against Value at 7.9 and asymmetric R:R of 9.26.
The strongest dimensions are Value at 7.9, Sentiment at 7.4, and Technical at 7.1; the weakest are Momentum at 2.1, Quality at 2.8, and Risk (lower is worse) at 3.0. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 9.26 and an engine sizing output of AVOID.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
Trip ifQuality score stays below 2.5 from current 2.8 for 2 consecutive quarters.
Trip ifAnalyst target falls below $15 from $24.44.
Trip ifQuarterly EPS loss exceeds $1.25 per share.
Trip ifInsider selling exceeds 0.5% of market cap over 90 days.
Trip ifShare price falls below the $9.81 stop level, more than 4% below $10.23.